Læknablaðið - 01.06.2021, Blaðsíða 17

L ÆK N A BL AÐIÐ 2021/107 285
R A N N S Ó K N
Greinin barst til blaðsins 7. febrúar 2021,
samþykkt til birtingar 20. apríl 2021.
ósæðarlokuskipti.1 Engu að síður er árangur þessara tæknilega
flóknu aðgerða góður hér á landi, ekki síst þegar litið er á 30 daga
dánarhlutfall, 5 ára lifun og MACCE-fría lifun. Einnig er jákvætt
hversu hátt viðgerðarhlutfallið er og lág tíðni endurviðgerða, en
lengri eftirfylgd þarf til þess að fullyrða um langtímaárangur.
Heimildir
1. Arnórsson Þ, Torfason B, Ólafsson G, et al. Hjartaskurðlækningar á Íslandi í 20 ár. Ágrip
erinda og veggspjalda á Vísindaþinginu. Læknablaðið 2007; 93: 320.
2. SWEDEHEART. Annual Report 2019: Jernberg T, Danderyd Hospital, Stockholm 2019.
ucr.uu.se/swedeheart/dokument-sh/arsrapporter-sh/1-swedeheart-annual-report-2019/
viewdocument/2948 - apríl 2021.
3. Harb SC, Griffin BP. Mitral Valve Disease: a Comprehensive Review. Curr Cardiol Rep
2017; 19: 73.
4. Fishbein GA, Fishbein MC. Mitral Valve Pathology. Curr Cardiol Rep 2019; 21: 61.
5. Anyanwu AC, Adams DH. Etiologic classification of degenerative mitral valve disease:
Barlow's disease and fibroelastic deficiency. Semin Thorac Cardiovasc Surg 2007; 19: 90-6.
6. Gupta V, Barzilla JE, Mendez JS, et al. Abundance and location of proteoglycans and
hyaluronan within normal and myxomatous mitral valves. Cardiovasc Pathol 2009; 18:
191-7.
7. Hjortnaes J, Keegan J, Bruneval P, et al. Comparative Histopathological Analysis of Mitral
Valves in Barlow Disease and Fibroelastic Deficiency. Semin Thorac Cardiovasc Surg 2016;
28: 757-67.
8. Coutinho GF, Antunes MJ. Mitral valve repair for degenerative mitral valve disease: sur-
gical approach, patient selection and long-term outcomes. Heart 2017; 103: 1663-9.
9. Gudmundsdóttir JF, Ragnarsson S, Geirsson A, et al. Árangur míturlokuviðgerða á Íslandi
2001-2012. Læknablaðið 2014; 100: 579-84.
10. Michler RE, Smith PK, Parides MK, et al. Two-Year Outcomes of Surgical Treatment of
Moderate Ischemic Mitral Regurgitation. N Engl J Med 2016; 374: 1932-41.
11. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of
valvular heart disease. Eur Heart J 2017; 38: 2739-91.
12. De Bonis M, Alfieri O, Dalrymple-Hay M, et al. Mitral Valve Repair in Degenerative Mitral
Regurgitation: State of the Art. Prog Cardiovasc Dis 2017; 60: 386-93.
13. Ragnarsson S, Sigurðsson MI, Danielsen R, et al. Árangur míturlokuskipta á Íslandi.
Læknablaðið 2012; 98: 203-9.
14. Kaneko T, Cohn LH. Mitral valve repair. Circ J 2014; 78: 560-6.
15. David TE, Armstrong S, McCrindle BW, et al. Late outcomes of mitral valve repair for
mitral regurgitation due to degenerative disease. Circulation 2013; 127: 1485-92.
16. Cuartas MM, Davierwala PM. Minimally invasive mitral valve repair. Indian J Thorac
Cardiovasc Surg 2020; 36 (Suppl 1): 44-52.
17. Guðbjartsson T, Andersen K, Danielsen R, et al. Yfirlitsgrein um kransæðasjúkdóm:
Faraldsfræði, meingerð, einkenni og rannsóknir til greiningar. Læknablaðið 2014; 100: 667-
676.
18. Campeau L. Letter: Grading of angina pectoris. Circulation 1976; 54: 522-3.
19. Joint Task Force on the Management of Valvular Heart Disease of the European Society
of Cardiology, European Association for Cardio-Thoracic Surgery, Vahanian A, et al.
Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;
33: 2451-96.
20. EuroSCORE II 2020. euroscore.org/calc.html - apríl 2021.
21. Doyle DJ, Garmon EH. American Society of Anesthesiologists Classification (ASA Class).
StatPearls. Flórída 2020.
22. Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical
and comprehensive review. Clin Kidney J 2013; 6: 8-14.
Þakkir
Þakkir fá sérfræðingar á hjarta- og lungnaskurðdeild Landspítala
og á gjörgæsludeild og hjartadeild Landspítala. Rannsóknin var
styrkt af Vísindasjóði Landspítala, Rannsóknarsjóði Háskóla Ís-
lands og Minningarsjóði Helgu Jónsdóttur og Sigurliða Kristjáns-
sonar.
23. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction
(2018). J Am Coll Cardiol 2018; 72: 2231-64.
24. Hagstofa Íslands . Lykiltölur mannfjöldans 1703-2020. px.hagstofa.is/pxis/pxweb/is/Ibuar/
Ibuar__mannfjoldi__1_yfirlit__Yfirlit_mannfjolda/MAN00000.px - apríl 2020.
25. The Human Mortality Database 2020. mortality.org/ - apríl 2020.
26. Suri RM, Clavel M-A, Schaff HV, et al. Effect of Recurrent Mitral Regurgitation Following
Degenerative Mitral Valve Repair: Long-Term Analysis of Competing Outcomes. J Am Coll
Cardiol 2016; 67: 488-98.
27. Sideris K, Boehm J, Voss B, et al. Functional and Degenerative Mitral Regurgitation: One
Ring Fits All? Thorac Cardiovasc Surg 2019; 68: 470-7.
28. Poçi D. Mitral Regurgitation, Atrial Fibrillation, and Transcatheter Mitral Valve Repair.
JACC Cardiovasc Interv 2019; 12: 579-81.
29. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management
of patients with valvular heart disease: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg
2014; 148: e1-e132.
30. Hamandi M, Ryan WH, Grayburn PA, et al. Misclassification of Mitral Valve Disease and
Rate of Surgical Repair in The Society of Thoracic Surgeons Database. Ann Thorac Surg
2020; 110: 517-22.
31. Jimenez E, Wu D, Omer S, et al. Mitral Valve Repair Rate at a Veterans Affairs Hospital
Utilizing a Multidisciplinary Heart Team. Semin Thorac Cardiovasc Surg 2019; 31: 434-41.
32. David TE, David CM, Fan CS, et al. Tricuspid regurgitation is uncommon after mitral
valve repair for degenerative diseases. J Thorac Cardiovasc Surg 2017; 154: 110-22.
33. Ad N, Holmes SD, Massimiano PS, et al. The effect of the Cox-maze procedure for atrial
fibrillation concomitant to mitral and tricuspid valve surgery. J Thorac Cardiovasc Surg
2013; 146: 1426-34; discussion 34-5.
34. Oddsson SJ, Sigurjónsson H, Helgadottir S, et al. Tengsl offitu við árangur kransæða-
hjáveituaðgerða. Læknablaðið 2011; 97: 223-8.
35. Ingvarsdottir IL. Viktorsson SA, Hreinsson K, et al. Lokuskipti vegna ósæðarlokuþrengsla
á Íslandi 2002-2006: Ábendingar og snemmkomnir fylgikvillar. Læknablaðið 2011; 97: 523-
7.
36. Ram E, Schwammenthal E, Cohen H, et al. Outcomes of Degenerative Mitral Valve Repair
Surgery for Anterior, Posterior, and Bileaflet Pathology. Ann Thorac Surg 2020; 110: 934-
42.
37. Borde D, Gandhe U, Hargave N, et al. The application of European system for cardiac
operative risk evaluation II (EuroSCORE II) and Society of Thoracic Surgeons (STS)
risk-score for risk stratification in Indian patients undergoing cardiac surgery. Ann Card
Anaesth 2013; 16: 163-6.
38. Gardner MA, Hossack KF, Smith IR. Long-Term Results Following Repair for
Degenerative Mitral Regurgitation - Analysis of Factors Influencing Durability. Heart
Lung Circ 2019; 28: 1852-65.
39. Costa F, Colatusso DFF, Martin G, et al. Long-Term Results of Mitral Valve Repair. Braz J
Cardiovasc Surg 2018; 33: 23-31.
40. Johannesdottir H, Arnadottir LO, Adalsteinsson JA, et al. Favourable long-term outcome
after coronary artery bypass grafting in a nationwide cohort. Scand Cardiovasc J 2017; 51:
327-33.
41. Watt TMF, Brescia AA, Murray SL, et al. Degenerative Mitral Valve Repair Restores Life
Expectancy. Ann Thorac Surg 2020; 109: 794-801.